至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

A bioorthogonal probiotic platform spatiotemporally releases nanobodies in deep tumor for cancer chemoimmunotherapy

Materials Today . 2024-09; 
Ruiyue Chen , Qianglan Lu , Fei Zeng , Shurong Qin , Yongchun Pan , Zhiyong Liu , Yuzhen Wang , Bangshun He , Wenjin Qi , Yujun Song
Products/Services Used Details Operation
Recombinant Proteins nterleukin-4 (IL-4) and Granulocyte Macro-phage Colony Stimulating Factor (GM-CSF) were obtained from GenScript Biotech Corporation. All antibodies for flow cytometry analysis were used from BioLegend (USA). Get A Quote

摘要

The effectiveness of immune checkpoint blockade therapies in treating solid tumors is hindered by the limited activation of the tumor immune microenvironment within deep tumors. Immunogenic cell death offers a promising method to enhance anti-tumor immune responses. Integrating these two approaches in cancer chemoimmunotherapy presents a novel perspective. Here, a self-mineralized bioorthogonal probiotic platform with the expression of anti-PD-L1 nanobodies was developed for cancer chemoimmunotherapy. This platform selectively accumulated and deeply penetrated into tumor tissues, where the palladium-mineralized probiotics catalyzed bioorthogonal bond-cleavage to generate chemotherapeutic drugs and induced immun... More

关键词